exhibit 10. 2execution versionconfidentialassignment, assumption and novation agreementthis assignment, assumption and novation agreement ( this “ agreement ” ), dated as of may 13, 2021 ( the “ effective date ” ), is by and among roivant sciences ltd. ( “ roivant ” ), roivant china holdings ltd. ( “ roivant china ” ), sinovant sciences hk limited ( “ sinovant hk ” ), sinovant sciences co., ltd. ( “ sinovant, ” and together with roivant, roivant china and sinovant hk, the “ assignors ” ), sumitomo pharmaceuticals ( suzhou ) co., ltd. ( “ assignee ” ), sumitomo dainippon pharma co., ltd. ( “ assignee parent ” ), nabriva therapeutics ireland designated activity company ( “ nabriva ireland ” ), and nabriva therapeutics gmbh ( “ nabriva therapeutics, ” and together with nabriva ireland, “ nabriva ” ). each of assignors, assignee, assignee parent, nabriva ireland and nabriva therapeutics may be referred to herein as a “ party ” and collectively, the “ parties ” hereunder. w i t n e s s e t h : whereas, ( i ) assignors and nabriva are parties to that certain license agreement dated as of march 26, 2018, as amended on october 29, 2020 ( the “ nabriva license agreement ” ) ; ( ii ) roivant china, sinovant hk and nabriva ireland are parties to that certain technology transfer agreement, dated as of october 21, 2020 ( the “ nabriva technology transfer agreement ” ) ; ( iii ) roivant china, sinovant hk, sinovant and nabriva ireland are parties to that certain trademark license agreement, dated as of may 11, 2020 ( the “ nabriva trademark agreement ” ) ; ( iv ) sinovant hk, sinovant and nabriva ireland are parties to that certain safety data exchange agreement, dated august 2, 2019 ( the “ nabriva safety data exchange agreement ” ) ; and ( v ) sinovant hk, sinovant and nabriva ireland are parties to that certain agreement for the manufacture & supply of clinical trial material, dated as of october 4, 2019 ; ( the “ nabriva manufacture agreement ” ) ;